Pharmacology News

Nearly 90% of adults with chronic inflammatory disease who were taking immunosuppressive medication had an antibody response after receiving an mRNA vaccine for SARS-CoV-2, according to findings in Annals of Internal Medicine.

Anticipated results of the EMPEROR-Preserved trial demonstrate that the SGLT2 inhibitor empagliflozin improved clinical outcomes in patients with HF with preserved ejection fraction — the first agent to be shown to do so.

For patients with unstable angina or non-STEMI referred for coronary angiography, the use of fentanyl as an analgesic for chest pain slowed the absorption of ticagrelor, resulting in greater platelet reactivity compared with lignocaine.

In patients with prior MI from the REDUCE-IT cohort, icosapent ethyl reduced risk for first and total CV events compared with placebo, according to new data presented at the European Society of Cardiology Congress.

Researchers reported that prenatal use of antipsychotics was not associated with risks for adverse outcomes in children — specifically, ADHD, autism spectrum disorder, preterm birth or being born small for gestational age.

Greater use of opioid alternatives for the treatment of pain in patients with CVD and expanded public training in the recognition and treatment of overdose may stem the contemporary rise in opioid-related deaths, a committee wrote.

Boehringer Ingelheim and Eli Lilly announced the FDA has approved empagliflozin to reduce risk for CV death and HF hospitalization in adults with HF with reduced ejection fraction regardless of whether they have diabetes.

Dexamethasone, “an evidence-based treatment” for COVID-19, might have been “underused” among patients with the condition who required ventilation, researchers of a retrospective study wrote.

In a simulation model, the addition of dapagliflozin to guideline-directed medical therapy in patients with HF with reduced ejection fraction improved long-term clinical outcomes while proving cost-effective at current U.S. prices.

Recent data revealed an increase in medication use among nursing home residents in Ontario, Canada, “with the potential for adverse effects” during the COVID-19 pandemic, according to researchers.